Stock Price
2.33
Daily Change
-0.04 -1.69%
Monthly
-20.48%
Yearly
76.52%
Q2 Forecast
2.28

Galectin Therapeutics reported $27.65M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Gilead Sciences USD 59.02B 490M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Merck USD 129.55B 12.02B Sep/2025